Stevanato Group drops after Q1 results; FY2026 EPS outlook trails expectations
Stevanato Group reported Q1 2026 results this morning and maintained full-year 2026 guidance. The maintained EPS outlook (€0.59–€0.63) was below widely cited expectations, which likely pressured the stock.
1. What happened today (May 7, 2026)
Stevanato Group released first-quarter 2026 financial results pre-market and reiterated its fiscal 2026 guidance. The update included revenue of €273.6 million and adjusted EPS of €0.11 for the quarter, alongside unchanged full-year targets.
2. The catalyst behind the move
Despite in-line/near in-line quarterly performance, the reiterated full-year profitability outlook appears to have disappointed: FY2026 adjusted diluted EPS guidance of €0.59–€0.63 was cited as below consensus expectations. That guidance gap is a concrete same-day catalyst consistent with the stock trading lower.
3. Key details from the release
The company highlighted 7% reported revenue growth (10% constant currency), improved adjusted EBITDA margin (23.9%), and continued scaling benefits at newer facilities, while noting headwinds such as higher depreciation, FX impacts, and tariffs. It also discussed strong demand tied to biologics/GLP-1, with GLP-1s representing roughly 21%–22% of total company revenue in the quarter.